GlassScriptPhysician profile
Thomas A Vines
NPI 1083634281
$7,048.99
in general payments reported to CMS, 2019-2025
35 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $2,378 · 2021: $1,114 · 2023: $158 · 2024: $265 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,675.87 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $1,019.42 | 2019-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.30 | 2019-2021 | |
| Pfizer INC. | $521.32 | 2019-2021 | |
| Csl Behring | $462.60 | 2019-2021 | |
| Electromed, INC. | $307.82 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $269.46 | 2019-2020 | |
| Insmed, INC. | $264.99 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $248.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $243.46 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $235.29 | 2019-2021 | |
| Mylan Specialty L.P. | $223.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $177.02 | 2019-2020 | |
| Grifols USA, LLC | $116.08 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $95.09 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $69.91 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $68.45 | 2019-2021 | |
| Eisai INC. | $45.24 | 2020-2021 | |
| Optinose US, INC. | $41.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.86 | 2020-2021 | |
| Gilead Sciences, INC. | $39.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $37.31 | 2020-2021 | |
| Shire North American Group INC | $37.07 | 2019 | |
| Inspire Medical Systems, INC. | $33.27 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $31.97 | 2020 | |
| Biofire Diagnostics, LLC | $26.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.02 | 2020-2021 | |
| Amgen INC. | $19.93 | 2025 | Tezspire |
| Olympus America INC. | $19.72 | 2021 | |
| Allergan, INC. | $19.14 | 2019 | |
| United Therapeutics Corporation | $17.80 | 2021 | |
| Vapotherm INC | $17.32 | 2019 | |
| Nabriva Therapeutics, Plc | $16.83 | 2020 | |
| Pulmonx Corporation | $16.29 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Genzyme Corporation | $15.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.